What is Syncromune?
Syncromune is a clinical-stage biopharmaceutical firm focused on developing an in situ platform therapy for metastatic solid tumor cancers. The company's lead candidate, SYNC-T, is a personalized therapy designed to combine partial tumor oncolysis with a multi-target biologic drug. This innovative approach aims to activate the immune system directly within the tumor microenvironment, promoting systemic immune activation and combating immunosuppression. By enabling T cells to recognize and attack cancer throughout the body, Syncromune seeks to achieve higher response rates and potentially improve patient survival, while also establishing immune memory.
How much funding has Syncromune raised?
Syncromune has raised a total of $100M across 1 funding round:
Series A
$100M
Series A (2024): $100M, investors not publicly disclosed
What's next for Syncromune?
The recent major strategic investment, alongside the overall enterprise-level funding context, suggests Syncromune is poised for significant scaling and advancement of its clinical pipeline. This capital infusion is likely to accelerate the ongoing Phase 1 trials for its first two candidates, SV-101 and SV-102. The company's focus on activating the immune system in situ for solid tumors positions it within a highly competitive and rapidly evolving oncology landscape. Future developments will likely center on demonstrating robust clinical efficacy, expanding trial indications, and potentially preparing for later-stage development or strategic partnerships.
See full Syncromune company page
